AN2 director granted 20,400 stock options

Marks Gilbert Lynn reported acquisition or exercise transactions in this Form 4 filing.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Marks Gilbert Lynn reported acquisition or exercise transactions in this Form 4 filing.

AN2 Therapeutics director Marks Gilbert Lynn reported receiving a grant of stock options covering 20,400 shares. The options are scheduled to vest on February 20, 2027, provided he continues to provide service to the company through that date.

Insider Trade Summary

Grant/Award: 20,400 shares

Grant/Award 1 txn

Insider Marks Gilbert Lynn

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	20,400	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 20,400 contracts (Direct)

Footnotes (1)

F1. The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AN2 Therapeutics (ANTX) report for Marks Gilbert Lynn?

AN2 Therapeutics reported a stock option grant for director Marks Gilbert Lynn covering 20,400 shares. The Form 4 shows this as an acquisition of derivative securities, increasing his directly owned option holdings to 20,400 shares after the transaction.

When do the newly granted AN2 Therapeutics (ANTX) stock options vest?

The 20,400 AN2 Therapeutics stock option shares are scheduled to vest on February 20, 2027. Vesting is conditioned on Marks Gilbert Lynn providing continuous service to the company through that specific vesting date, according to the footnote disclosure.

How many AN2 Therapeutics (ANTX) option shares does Marks Gilbert Lynn hold after this filing?

After the reported transaction, Marks Gilbert Lynn holds 20,400 AN2 Therapeutics stock option shares directly. This total equals the amount granted in the transaction, indicating the award established his current reported option holdings in the company.

Is the AN2 Therapeutics (ANTX) stock option award to Marks Gilbert Lynn a direct holding?

Yes. The Form 4 identifies the 20,400 stock option shares as directly owned by Marks Gilbert Lynn. The ownership code is marked as direct, and no footnote indicates that the options are held through a separate entity or trust.

What type of security was granted to Marks Gilbert Lynn by AN2 Therapeutics (ANTX)?

The filing describes the award as a “Stock Option (Right to Buy)” security. This is a derivative security that gives Marks Gilbert Lynn the right to acquire up to 20,400 AN2 Therapeutics shares, subject to the vesting condition on February 20, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/23/2026 - 04:29 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Marks Gilbert Lynn

(Last)

(First)

(Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK

94025

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$1.04	02/20/2026		A		20,400		⁽¹⁾	02/19/2036	Common Stock	20,400	$0	20,400	D

Explanation of Responses:

1. The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date.

	/s/ Lucy Day, Attorney-in-Fact for Gilbert Lynn Marks	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR